EVALUATION OF ANTIOXIDANT ACTIVITY AND STANDARDIZATION OF ACT 12 AND ACT 13 FORMULATIONS

Dr. Shridhar Jitubhai Pandya* and Chetan Himmatbhai Savaliya

ABSTRACT

Background and objective: COVID-19 is an infectious disease caused by the SARS-CoV-2 virus and spread over 211 countries worldwide and considered to be a pandemic. Globally on 28 August 2020, there are 24,299,923 confirmed subjects of COVID-19, including 827,730 deaths, and in India from Jan 30 2020 to 28 August 2020, there are 3,387,500 confirmed subjects and 61,529 deaths were reported. Covid-19 infection is due to the corona virus and leads to increased oxidative stress in the body, which leads to multiple-organ failure through various immune mechanisms. By considering the impact and intensity of the pandemic situation, Gplife Healthcare Pvt. Ltd. has come up with Act 12 and Act 13 formulations as the solution to reduce oxidative stress. Materials and Methods: Antioxidant activity of Act 12 and Act 13 was evaluated In-vitro by using DPPH scavenging assay, H2O2 radical scavenging assay, and Reducing power assay. Further, the standardization of both the formulations was performed by using the HPLC method. Results: The formulations Act 12 and Act 13 showed significant anti-oxidant action when compared with standard ascorbic acid. The percentage scavenging activity of Act 12 and Act 13 was found to be in the range of 18-53 % and 16-46 % respectively as compared to that of the standard at different concentrations. Conclusion: The study thus proves that Act 12 and Act 13 have significant antioxidant activities.

Keywords: Oxidative stress; Antioxidant; COVID-19; Standardization; herbal formulation.